JP2022515650A - キナーゼ阻害剤化合物及び組成物ならびに使用方法 - Google Patents

キナーゼ阻害剤化合物及び組成物ならびに使用方法 Download PDF

Info

Publication number
JP2022515650A
JP2022515650A JP2021538205A JP2021538205A JP2022515650A JP 2022515650 A JP2022515650 A JP 2022515650A JP 2021538205 A JP2021538205 A JP 2021538205A JP 2021538205 A JP2021538205 A JP 2021538205A JP 2022515650 A JP2022515650 A JP 2022515650A
Authority
JP
Japan
Prior art keywords
compound
purified
silica gel
column chromatography
gel column
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021538205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515650A5 (cg-RX-API-DMAC10.html
Inventor
ロバート ジェイ. デヴィータ
アンドリュー エフ. スチュワート
チャラダ スエブスウォング
クナル クマール
ペン ワン
ロベルト ジェイ. サンチェス
フイ ワン
Original Assignee
アイカーン スクール オブ メディシン アット マウント サイナイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイカーン スクール オブ メディシン アット マウント サイナイ filed Critical アイカーン スクール オブ メディシン アット マウント サイナイ
Publication of JP2022515650A publication Critical patent/JP2022515650A/ja
Publication of JP2022515650A5 publication Critical patent/JP2022515650A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021538205A 2018-12-31 2019-12-31 キナーゼ阻害剤化合物及び組成物ならびに使用方法 Pending JP2022515650A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862786991P 2018-12-31 2018-12-31
US62/786,991 2018-12-31
PCT/US2019/069059 WO2020142486A1 (en) 2018-12-31 2019-12-31 Kinase inhibitor compounds and compositions and methods of use

Publications (2)

Publication Number Publication Date
JP2022515650A true JP2022515650A (ja) 2022-02-21
JP2022515650A5 JP2022515650A5 (cg-RX-API-DMAC10.html) 2023-01-11

Family

ID=71407427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021538205A Pending JP2022515650A (ja) 2018-12-31 2019-12-31 キナーゼ阻害剤化合物及び組成物ならびに使用方法

Country Status (7)

Country Link
US (1) US20220064146A1 (cg-RX-API-DMAC10.html)
EP (1) EP3906028A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022515650A (cg-RX-API-DMAC10.html)
CN (1) CN113543783A (cg-RX-API-DMAC10.html)
AU (1) AU2019418800A1 (cg-RX-API-DMAC10.html)
CA (1) CA3124353A1 (cg-RX-API-DMAC10.html)
WO (1) WO2020142486A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019100062A1 (en) 2017-11-20 2019-05-23 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
JP2021510153A (ja) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
JPWO2023008470A1 (cg-RX-API-DMAC10.html) * 2021-07-28 2023-02-02
TW202513069A (zh) 2023-07-21 2025-04-01 美商冰洲石生物科技公司 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008516974A (ja) * 2004-10-15 2008-05-22 アベンティス・ファーマスーティカルズ・インコーポレイテツド プロスタグランジンd2受容体アンタゴニストとしての2,6−置換−4−一置換アミノ−ピリミジン
JP2013525377A (ja) * 2010-04-23 2013-06-20 サイトキネティクス・インコーポレーテッド ある種のアミノ−ピリミジン、その組成物、及びそれを用いるための方法
JP2013525376A (ja) * 2010-04-23 2013-06-20 サイトキネティクス・インコーポレーテッド 特定のアミノピリダジン、その組成物、及びこれらの使用方法
JP2015514804A (ja) * 2012-04-24 2015-05-21 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Dna−pk阻害剤
WO2018098561A1 (en) * 2016-12-01 2018-06-07 Aptose Biosciences Inc. Fused pyrimidine compounds as brd4 and jak2 dual inhibitors and methods for use thereof
WO2018210994A1 (en) * 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators
JP2018534328A (ja) * 2015-11-20 2018-11-22 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd Pge2レセプター調節剤としてのn−置換インドール誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200301123A (en) * 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2011058139A1 (en) * 2009-11-12 2011-05-19 Selvita Sp. Z O. O. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
US20130102627A1 (en) * 2010-04-09 2013-04-25 The Brigham And Women's Hospital, Inc. Acridines As Inhibitors Of Haspin And DYRK Kinases
KR102006749B1 (ko) * 2011-08-19 2019-08-02 디악쏘니 Dyrk1 억제제 및 이의 용도
SI3057959T1 (en) * 2013-10-17 2018-07-31 Vertex Pharmaceuticals Incorporated DNA-PK INHIBITORS
AU2016315881B2 (en) * 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008516974A (ja) * 2004-10-15 2008-05-22 アベンティス・ファーマスーティカルズ・インコーポレイテツド プロスタグランジンd2受容体アンタゴニストとしての2,6−置換−4−一置換アミノ−ピリミジン
JP2013525377A (ja) * 2010-04-23 2013-06-20 サイトキネティクス・インコーポレーテッド ある種のアミノ−ピリミジン、その組成物、及びそれを用いるための方法
JP2013525376A (ja) * 2010-04-23 2013-06-20 サイトキネティクス・インコーポレーテッド 特定のアミノピリダジン、その組成物、及びこれらの使用方法
JP2015514804A (ja) * 2012-04-24 2015-05-21 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Dna−pk阻害剤
JP2018534328A (ja) * 2015-11-20 2018-11-22 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd Pge2レセプター調節剤としてのn−置換インドール誘導体
WO2018098561A1 (en) * 2016-12-01 2018-06-07 Aptose Biosciences Inc. Fused pyrimidine compounds as brd4 and jak2 dual inhibitors and methods for use thereof
WO2018210994A1 (en) * 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HETEROCYCLES, vol. 96, no. 9, JPN6024004273, 2018, pages 1549 - 1569, ISSN: 0005399923 *
REGISTRY(STN)[ONLINE], JPN7024000399, ISSN: 0005399924 *

Also Published As

Publication number Publication date
CN113543783A (zh) 2021-10-22
CA3124353A1 (en) 2020-07-09
AU2019418800A1 (en) 2021-07-01
WO2020142486A1 (en) 2020-07-09
EP3906028A4 (en) 2022-10-12
US20220064146A1 (en) 2022-03-03
EP3906028A1 (en) 2021-11-10

Similar Documents

Publication Publication Date Title
US12421232B2 (en) Kinase inhibitor compounds and compositions and methods of use
US20230234935A1 (en) Kinase inhibitor compounds and compositions and methods of use
US20220064146A1 (en) Kinase inhibitor compounds and compositions and methods of use
US8697700B2 (en) Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
KR101892574B1 (ko) 디아릴아세틸렌 히드라지드 함유 티로신 키나제 억제제
AU2011217561B2 (en) Hetarylaminonaphthyridines
EP3906233B1 (en) Kinase inhibitor compounds and compositions and methods of use
US10112950B2 (en) Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US20250215013A1 (en) Substituted tricyclic compounds as parp inhibitors and the use thereof
EP3672958B1 (en) Annulated glycosidase inhibitors
US20230089368A1 (en) Polyaromatic urea derivatives and their use in the treatment of muscle diseases
US11547712B2 (en) Kinase inhibitor compounds and compositions and methods of use
US20210122763A1 (en) Oga inhibitor compounds
HK40063467A (en) Kinase inhibitor compounds and compositions and methods of use
HK40062251A (en) Kinase inhibitor compounds and compositions and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230824

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240826